Search Results
Mar 19, 2026, 20:50 ET Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at ECO 2026
Preclinical data on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for oral presentation at the European Congress on Obesity (ECO 2026).The presentation will be delivered by Arya M. Sharma, MD, Caliway's
More news about: Caliway Biopharmaceuticals
Mar 19, 2026, 12:04 ET FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile
expands its already robust label inclusive of multiple formulations, including Wegovy® pill, and indications not available with other GLP-1 weight loss medicinesPLAINSBORO, N.J., March 19, 2026
More news about: NOVO NORDISK INC.
Mar 19, 2026, 08:00 ET Endevica Announces Spinout of Kalohexis to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic Diseases
cancers710GO has shown healthier, more durable weight loss without lean body mass loss and other side effects common with GLP-1 receptor agonists NORTHBROOK, Ill., March 19, 2026 /PRNewswire/
More news about: Endevica Bio
Mar 19, 2026, 08:00 ET Kalohexis Emerges from Stealth to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic Diseases
cancers710GO has shown healthier, more durable weight loss without lean body mass loss and other side effects common with GLP-1 receptor agonists NORTHBROOK, Ill., March 19, 2026 /PRNewswire/
More news about: Kalohexis
Mar 19, 2026, 07:30 ET Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
trial participants. In nonclinical studies in obese mouse models, taldefgrobep, both as monotherapy and in combination with a GLP-1 agonist, generated significant reductions in fat mass and body weight, while increasing lean mass. NEW
More news about: Biohaven Ltd.
Mar 19, 2026, 06:45 ET Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
results from TRANSCEND-T2D-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, as an adjunct to diet and exercise. The trial enrolled adults diagnosed with type 2 diabetes with
More news about: Eli Lilly and Company
Mar 19, 2026, 06:30 ET DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
further reinforcing Dario's position as a leader in digital health.Dario's oral GLP-1 digital health solution is positioned to amplify the positive impacts of GLP-1 medication, improving ROI for employers and health plans in one of the fastest growing expense centers
More news about: DarioHealth Corp.
Mar 18, 2026, 08:00 ET MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
Company's Phase 1 Part 3 clinical trial of its lead asset, DA-1726, a novel, dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors. The approval enables initiation of Part 3 of the Phase 1 program, which consists of two 16-week titration cohorts
More news about: MetaVia Inc.
Mar 17, 2026, 13:17 ET As GLP-1 Weight Loss Reshapes Aesthetic Trends, NicholsMD Introduces AlloClae, a Next-Generation Treatment for Non-Surgical Body Contouring in Connecticut
As GLP-1 medications continue to gain momentum nationwide, many patients are experiencing significant weight reduction that can leave behind areas of volume
More news about: NicholsMD of Greenwich
Mar 17, 2026, 12:30 ET Maven Clinic Introduces Maven Intelligence, an AI-Powered Orchestration Layer for Women's and Family Health
scale. Through its consumer platform, Maven provides direct access to virtual care across 30+ specialties, as well as dedicated hormone and GLP-1 care programs purpose-built for women.Founded in 2014 by CEO Kate Ryder, Maven Clinic has raised more than $425 million from leading healthcare
More news about: Maven Clinic
Mar 17, 2026, 11:00 ET PatientPoint Launches the Consumer Health Network Helping Consumer Brands Reach High-Intent Consumers in Trusted Healthcare Settings
limited to 200 million healthy agers3,31 million allergy sufferers3,27 million GLP-1 users3By connecting brands with consumers during preventive visits, chronic care appointments and wellness check-ins,
More news about: PatientPoint
Mar 17, 2026, 10:53 ET DELIVERING THE FUTURE
high-performance subcutaneous delivery solutions."With hundreds of millions of disposable auto-injectors discarded annually to administer biologics like GLP-1s, sustainability and cost efficiency are becoming central considerations for pharmaceutical partners worldwide.PRIME NEXUS™ combines a durable
More news about: Portal Instruments, Inc.
Mar 17, 2026, 09:00 ET Lifeway Foods® Announces Strong Fourth Quarter and Record-Breaking Full Year 2025 Results Led by the Company's Flagship Kefir
awareness of GLP-1 medications and their impact on nutrition continues to surge, Lifeway stands uniquely positioned to serve both active GLP-1 users seeking nutrient-dense, gut-friendly foods and consumers looking for products that naturally stimulate GLP-1 hormone production.
More news about: Lifeway Foods, Inc.
Mar 17, 2026, 06:00 ET Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models
molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR
More news about: Ascletis Pharma Inc.
Mar 17, 2026, 06:00 ET 口服小分子胰澱素受體激動劑ASC39在臨床前模型中顯示出類似eloralintide的胰澱素選擇性與療效
潛力。」ASC39是一種對胰澱素具有選擇性的強效口服小分子胰澱素受體激動劑，正在既作為單藥開發，也作為與ASC30聯用（ASC30為歌禮口服小分子、已具備III期條件的GLP-1候選藥物）開發，以治療包括肥胖症在內的代謝性疾病。該新型口服小分子胰澱素項目強化了歌禮現有的胰澱素多肽候選藥物組合，包括ASC36（可每月一次至每季度一次皮下注射的胰澱素多肽單藥療法），以及ASC36與每月一次ASC35（GLP-1/GIP皮下注射多肽）的固定劑量復方組合。[1] Briere DA, Qu
More news about: 歌禮製藥有限公司
Mar 17, 2026, 03:46 ET GLP-1 Receptor Agonist Market to Hit USD 78.4 Billion by 2032, Growing at a CAGR of 3.66% with Rising Demand for Metabolic Disease Therapies | MarkNtel Advisors
pharmaceutical companies actively developing and commercializing GLP-1-based treatments.Global GLP-1 Receptor Agonist Market Key TakeawaysThe Global GLP-1 Receptor Agonist Market was valued at around USD 52.39 billion in 2025
More news about: MarkNtel Advisors
Mar 16, 2026, 11:30 ET Frost & Sullivan Identifies Top 50 Technologies Set to Shape a $1.25-$1.35 Trillion Market Opportunity by 2030
digital health and biotechnology are reshaping treatment paradigms while improving pharmaceutical development efficiency."Technologies such as GLP-1 receptor agonists and AI-enabled drug discovery are enabling scalable disease management while significantly accelerating therapeutic innovation,"
More news about: Frost & Sullivan
Mar 16, 2026, 11:30 ET Frost & Sullivan Identifies Top 50 Technologies Set to Shape a $1.25-$1.35 Trillion Market Opportunity by 2030
and biotechnology are reshaping treatment paradigms while improving pharmaceutical development efficiency."Technologies such as GLP-1 receptor agonists and AI-enabled drug discovery are enabling scalable disease management while significantly accelerating therapeutic
More news about: Frost & Sullivan
Mar 14, 2026, 10:00 ET From Liver to Lymph Support: How PureHealth Research is Leading the Charge in Premium Pure Health Products
balanced immune responseGLP-1 Activation Supplement – GLP ON features 9 synergistic ingredients,
More news about: PureHealth Research LLC
Mar 14, 2026, 00:33 ET Vimgreen's Novel A2AR Antagonist Receives CDE IND Approval for NASH/MASH Therapy
Sanxing Sun, President and CEO of Vimgreen Pharmaceuticals. "Its mechanism of action is highly differentiated from current THR-beta agonists and GLP-1 therapies. By leveraging the drug's unique ability to restore hepatic lipophagy while simultaneously resolving inflammation and fibrosis, we are
More news about: Vimgreen Pharmaceuticals
Mar 13, 2026, 09:30 ET Kroger Brings Zepbound® KwikPen to Retail Pharmacy, Expanding Access and Savings for Self-Pay Patients
PrescriptionPatients filling GLP-1 prescriptions at Kroger Family of Pharmacies have access to a range of services designed to support adherence, education, and long-term health outcomes, including:Personalized pharmacist counseling on how GLP-1 medications work, what
More news about: The Kroger Co.
Mar 12, 2026, 14:52 ET THE WEIGHT LOSS RESET: NEW SURVEY FINDS AMERICANS SHIFTING FROM "BEACH BODY" GOALS TO METABOLIC HEALTH, RESHAPING SNACKS, AT-HOME MEALS, AND GLP-1 ADOPTION
or eating at home more often to control intake.GLP-1 dominates among Rx users: Among respondents who report using prescription weight loss medications or supplements, 72.7% report taking a GLP-1 medication, and 80.6% plan to continue long-term.Metabolic
More news about: aytm
Mar 12, 2026, 09:15 ET New Peer-Reviewed Research Shows Comprehensive Care Model Drives Superior GLP-1 Outcomes
roadmap for comprehensive GLP-1 care delivery through virtual care models. For the system, maximizing GLP-1 therapy value may require investment in care infrastructure, not just medication
More news about: Ivim Health
Mar 12, 2026, 09:01 ET MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In
More news about: MetaVia Inc.
Mar 12, 2026, 08:00 ET Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management
a day (10.4% increase)2 in a healthy glucose range (70–180 mg/dL). Participants were on basal insulin with either an SGLT2 inhibitor or a GLP‑1 receptor agonist, indicating meaningful benefit even among people already on advanced glucose-lowering therapies."This study demonstrates the
More news about: Abbott